Semaglutide gains partly rebound after stopping in HIV lipohypertrophy trial

The wire

1. 01In a phase 2b randomized, double-blind trial (NCT04019197), 108 people with HIV-associated lipohypertrophy took semaglutide or placebo for 32 weeks, then were followed off drug to week 56; 80 completed that phase.
2. 02Former semaglutide recipients regained weight, BMI, waist circumference, total body fat and visceral adipose tissue with worsening glycemic indices, though net reductions versus baseline persisted at week 56.
3. 03Authors conclude sustained pharmacologic exposure is likely needed for long-term benefit; the post-treatment phase was observational and attrition reduced the analyzed sample.

From the source

Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial

Open forum infectious diseases · 2026 Oct · Adekunle RO, Wu Q, Sattar A et al.